Kristie L. Kahl | Authors

Cobimetinib Plus Vemurafenib Produces Antitumor Activity in Patients With BRAF Mutations

June 07, 2022

Results from a cohort of the TAPUR study showed that the combination of cobimetinib plus vemurafenib demonstrated antitumor activity among patients with BRAF mutations who are not otherwise eligible for treatment with other FDA-approved therapies.

Adding Ibrutinib to FCR Combo Shows Promise as Time-Limited Therapy in Younger Patients With CLL

December 14, 2021

The time-limited combination of ibrutinib plus chemoimmunotherapy in younger fit patients with chronic lymphocytic leukemia increased the rate of complete responses with bone marrow undetectable minimal residual disease, regardless of IGHV mutation, according to long-term follow-up data.

Adding Eryaspase to Chemotherapy Shows Promise in Patients with ALL at Risk for Hypersensitivity Reactions

December 12, 2021

The infusion of E-Coli- and Erwinia-derived asparaginase therapies combined with chemotherapy appeared to be well tolerated with biological efficacy in patients with acute lymphoblastic leukemia under the age of 55, providing an additional option for patients for whom further asparagine treatment is contraindicated due to toxicity.